Drugs / ICP-488
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05451199 | Jul 2022 → Oct 2023 | psoriasis | Beijing InnoCare Pharma Tech Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT07440537 | Apr 2026 → Mar 2027 expected | cutaneous lupus erythematosus | Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06109818 | Jan → Aug 2024 | psoriasis | Beijing InnoCare Pharma Tech Co., Ltd. | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT06842199 | Mar 2025 → May 2026 overdue | psoriasis | Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-07-27 | Beijing InnoCare Pharma Tech Co., Ltd. | Results 诺诚健华新型TYK2抑制剂Fadeucravacitinib（ICP-488）治疗银屑病注册III期研究达到主要终点 innocarepharma.com ↗
结果显示，fadeucravacitinib在注册III期临床研究中达到主要终点，具有高度显著统计学意义和临床意义的改善。 |
| 2026-05-08 | Beijing InnoCare Pharma Tech Co., Ltd. | Regulatory 诺诚健华新型TYK2抑制剂ICP-488治疗干燥综合征II期临床试验获CDE批准 innocarepharma.com ↗
2026年5月8日，中国北京——生物医药高科技公司诺诚健华（上交所代码：688428；香港联交所代码：09969）今日宣布，公司自主研发的新型TYK2抑制剂（ICP-488）治疗干燥综合征获国家药品监督管理局（NMPA）药品审评中心（CDE）批准开展II期临床试验。 |
| 2024-10-09 | Beijing InnoCare Pharma Tech Co., Ltd. | Results 诺诚健华新型TYK2抑制剂ICP-488 治疗中重度银屑病II期研究达到主要终点 innocarepharma.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-27 | Beijing InnoCare Pharma Tech Co., Ltd. | 诺诚健华新型TYK2抑制剂Fadeucravacitinib（ICP-488）治疗银屑病注册III期研究达到主要终点 innocarepharma.com ↗ |
| 2026-05-08 | Beijing InnoCare Pharma Tech Co., Ltd. | 诺诚健华新型TYK2抑制剂ICP-488治疗干燥综合征II期临床试验获CDE批准 innocarepharma.com ↗ |
| 2024-10-09 | Beijing InnoCare Pharma Tech Co., Ltd. | 诺诚健华新型TYK2抑制剂ICP-488 治疗中重度银屑病II期研究达到主要终点 innocarepharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICP-488 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06109818 ↗ |
| Route | Oral | “ICP-488 will be administered as tablet” NCT06109818 ↗ |